Last reviewed · How we verify

NCT06658613

Pediatric Bronchoscopy and LUS

Completed Last updated 10 June 2025
What this trial tests

trial in Atelectasis in 30 participants. Completed in 1 May 2025.

Timeline
25 October 2024
Primary endpoint
1 May 2025
1 May 2025

Quick facts

Lead sponsorMarmara University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date25 October 2024
Primary completion1 May 2025
Estimated completion1 May 2025
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Marmara University

Who can join

Adults 1 to 17, any sex, with Atelectasis or Atelectasis, Postoperative Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rigid bronchoscopy is commonly used for diagnosing and treating lung and airway diseases, including foreign body removal. Patients often experience atelectasis post-procedure, which lung ultrasound (LUS) can effectively detect. LUS is a rapid, noninvasive imaging technique that provides real-time evaluation without the need for patient transportation. In this observational study, researchers will assess the incidence and severity of atelectasis in patients undergoing elective rigid bronchoscopy, comparing those who were intubated and awakened post-procedure with those who were not intubated. The study aims to determine whether intubation influences the development of atelectasis after bronchoscopy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atelectasis

Currently open trials in the same condition.

Other Marmara University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06658613.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing